...
首页> 外文期刊>Annals of allergy, asthma, and immunology >Increased cow's milk protein-specific IgG4 levels after oral desensitization in 7-to 12-month-old infants
【24h】

Increased cow's milk protein-specific IgG4 levels after oral desensitization in 7-to 12-month-old infants

机译:口服脱敏后7至12个月大婴儿的牛奶蛋白特异性IgG4水平升高

获取原文
获取原文并翻译 | 示例

摘要

Background Cow's milk protein (CMP)-specific IgG4 responses and the efficacy of oral desensitization in infants with cow's milk allergy (CMA) warrant more clarification. Objective To explore whether CMP-specific IgG4 responses develop during infancy and whether regular CM exposure is efficacious for inducing a CMP-specific IgG4 response accompanying CM desensitization in 7- to 12-month-old infants. Methods CM-specific IgE and CMP (α-lactalbumin, β-lactoglobulin, and casein)-specific IgG4 levels were measured in 262 CM-sensitized children. Of these, 31 infants 7 to 12 months old with challenge-proved CMA were randomly assigned to oral desensitization or an elimination diet and evaluated 6 months later. Results CMP-specific IgG4 levels in 7- to 12-month-old infants were higher than in those younger than 6 months but comparable to those in children older than 12 months. CMP-specific IgG4 levels in 7- to 12-month-old infants with CMA were significantly lower than in those without CMA. Fourteen of 16 patients receiving oral desensitization could accept daily doses of 200 mL of CM, whereas all but 3 dropout patients receiving the elimination diet still showed allergic symptoms at the follow-up food challenge. In patients who became desensitized, CM-specific IgE levels were lower than at baseline, whereas CMP-specific IgG4 levels were significantly increased. In patients receiving the elimination diet, CM-specific IgE and CMP-specific IgG4 levels remained unchanged. Conclusion CMP-specific IgG4 responses did not develop sufficiently in 7- to 12-month-old infants with CMA. Oral desensitization in 7- to 12-month-old infants with CMA was associated with the upregulation of CMP-specific IgG4 responses accompanying the alleviation of CMA symptoms.
机译:背景技术对患有牛奶过敏(CMA)的婴儿,牛奶蛋白(CMP)特异性IgG4反应和口服脱敏功效值得进一步阐明。目的探讨在婴儿期是否发生CMP特异性IgG4反应,以及在7到12个月大的婴儿中,常规CM暴露对于伴随CM脱敏引起的CMP特异性IgG4反应是否有效。方法对262名CM致敏儿童的CM特异性IgE和CMP(α-乳白蛋白,β-乳球蛋白和酪蛋白)特异性IgG4水平进行了测定。其中,将31例7至12个月大,经挑战验证的CMA婴儿随机分配为口服脱敏或消除饮食,并在6个月后进行评估。结果7至12个月大的婴儿的CMP特异性IgG4水平高于6个月以下的婴儿,但与12个月以上的儿童相当。患有CMA的7至12个月大婴儿的CMP特异性IgG4水平明显低于没有CMA的婴儿。在接受口服脱敏的16位患者中,有14位可以接受每日200 mL的CM剂量,而除了3位退出饮食的辍学患者,在接受后续食物挑战时仍然表现出过敏症状。在变得脱敏的患者中,CM特异性IgE水平低于基线水平,而CMP特异性IgG4水平则明显升高。在接受消除饮食的患者中,CM特异性IgE和CMP特异性IgG4水平保持不变。结论在7至12个月大的CMA婴儿中,CMP特异性IgG4反应没有得到充分发展。 7至12个月大CMA婴儿的口服脱敏与伴随CMA症状减轻的CMP特异性IgG4反应的上调有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号